Olprinone and colforsin daropate alleviate septic lung inflammation and apoptosis through CREB-independent activation of the Akt pathway

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 303, Issue 2, 2012, Pages

  Oishi, Hirofumi ^a   Takano, Ken Ichi ^a   Tomita, Kengo ^a   Takebe, Mariko ^a   Yokoo, Hiroki ^a   Yamazaki, Mitsuaki ^a   Hattori, Yuichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Acute lung injury; Adenylate cyclase activator; Phosphodiesterase III inhibitor; Polymicrobial sepsis

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; COLFORSIN DAROPATE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOPRINONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HYPOTENSION; HYPOXEMIA; IN VIVO STUDY; LUNG INJURY; MALE; MORTALITY; MOUSE; NONHUMAN; OSMOTIC PUMP; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; SEPSIS;

ACUTE LUNG INJURY; ANDROSTADIENES; ANIMALS; APOPTOSIS; CECUM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOKINES; ENZYME ACTIVATION; ENZYME ACTIVATORS; FORSKOLIN; HYPOTENSION; IMIDAZOLES; LIGATION; LUNG; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE INHIBITORS; PNEUMONIA; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; SHOCK, SEPTIC; SIGNAL TRANSDUCTION;

EID: 84863975277     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00363.2011     Document Type: Article

References (52)

1. Alves AC, Pires AL, Cruz HN, Serra MF, Diaz BL, Cordeiro RS, Lagente V, Martins MA. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur J Pharmacol 312: 89-96, 1996.
2. Ayala A, Chaudry IH. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6, suppl 1: S27-S38, 1996.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
4. Chang KC, Unsinger J, Davis CG, Schwulst SJ, Muenzer JT, Strasser A, Hotchkiss RS. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J 21: 708-719, 2007.
5. Chopra M, Reuben JS, Sharma AC. Acute lung injury: apoptosis and signaling mechanisms. Exp Biol Med (Maywood) 234: 361-371, 2009.
6. Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiesterase inhibition on the inflammatory response following shock: role of pentoxifylline. J Trauma 56: 442-449, 2004.
7. Connelly L, Madhani M, Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived NO in vivo. J Biol Chem 280: 10040-10046, 2005.
8. Dent G, Magnussen H, Rabe KF. Cyclic nucleotide phosphodiesterases in human lung. Lung 172: 129-146, 1994.
9. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators in the regulation of immune, lung, and neuronal function. Br J Pharmacol 159: 265-284, 2010.
10. Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277: 32124-32132, 2002.
11. Häfner D, Germann PG. Additive effects of phosphodiesterase-4 inhibition on effects of rSP-C surfactant. Am J Respir Crit Care Med 161: 1495-1500, 2000.
12. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto BM, McLoughlin M, Gallily R, Edwards CK 3rd, Schuchman EH, Fuks Z, Kolesnik R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 186: 1831-1841, 1997.
13. Haskó G, Cronstein B. Methylxanthines and inflammatory cells. Hand Exp Pharmacol 200: 457-468, 2011.
14. Hattori Y, Takano K, Teramae H, Yamamoto S, Yokoo H, Matsuda N. Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharm Sci 114: 354-365, 2010.
15. Hayashida N, Chihara S, Tayama E, Takaseya T, Enomoto N, Kawara T, Aoyagi S. Antiinflammatory effects of colforsin daropate hydrochloride, a novel water-soluble forskolin derivative. Ann Thorac Surg 71: 1931-1938, 2001.
16. Hong K, Lou L, Gupta S, Ribeiro-Neto F, Altschuler DL. A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation. J Biol Chem 283: 23129-23138, 2008.
17. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis in lymphoid and parenchyma cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med 25: 1298-1307, 1997.
18. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 162: 4148-4156, 1999.
19. Hoyle GW. Mitigation of chlorine lung injury by increasing cyclic AMP levels. Proc Am Thorac Soc 7: 284-289, 2010.
20. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH. Cecal ligation and puncture. Shock 24, Suppl 1: 52-57, 2005.
21. Iida M, Fujita N, Hosono M, Sukenaga Y. Bronchodilator and cardiovascular effects of NKH477, a novel water-soluble forskolin derivative, in guinea pigs. Jpn J Pharmacol 68: 245-253, 1995.
22. Kamiyama K, Matsuda N, Yamamoto S, Takano K, Takano Y, Yamazaki H, Kageyama S, Yokoo H, Nagata T, Hatakeyama N, Tsukada K, Hattori Y. Modulation of glucocorticoid receptor expression, inflammation, and cell apoptosis in septic guinea pig lungs using methylprednisolone. Am J Physiol Lung Cell Mol Physiol 295: L998-L1006, 2008.
23. Koike T, Nadeen Qutab M, Tsuchida M, Takekubo M, Saito M, Hayashi J. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulm Pharmacol Ther 21: 166-171, 2008.
24. Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: L622-L645, 2006.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
26. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1999 through 2000. N Engl J Med 348: 1546-1554, 2003.
27. Matsuda N, Hattori Y, Jesmin S, Gando S. Nuclear factor-κB decoy oligonucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 67: 1018-1025, 2005.
28. Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M, Gando S. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-κB on septic lungs in mice. Am J Physiol Lung Cell Mol Physiol 287: L1248-L1255, 2004.
29. Matsuda N, Hayashi Y, Takahashi Y, Hattori Y. Phosphorylation of endothelial nitric-oxide synthase is diminished in mesenteric arteries from septic rabbits depending on the altered phosphatidylinositol 3-kinase/Akt pathway: reversal effect of fluvastatin therapy. J Pharmacol Exp Ther 319: 1348-1354, 2006.
30. Matsuda N, Nishihira J, Takahashi Y, Kemmotsu O, Hattori Y. Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia. Am J Respir Cell Mol Biol 35: 198-205, 2006.
31. 4 receptors contributes to splenic apoptosis in septic mice: counteraction of the antiapoptotic action of nuclear factor-κB. J Pharmacol Exp Ther 332: 730-737, 2010.
32. Matsuda N, Yamamoto S, Takano K, Kageyama S, Kurobe Y, Yoshihara Y, Takano Y, Hattori Y. Silencing of Fas-associated death domain protects mice from septic lung inflammation and apoptosis. Am J Respir Crit Care Med 179: 806-815, 2009.
33. Matsuda N, Yamamoto S, Yokoo H, Tobe K, Hattori Y. Nuclear factor-κB decoy oligonucleotides ameliorate impaired glucose tolerance and insulin resistance in mice with cecal ligation and puncture-induced sepsis. Crit Care Med 37: 2791-2799, 2009.
34. Miotla JM, Teixeira MM, Hellewell PG. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am J Respir Cell Mol Biol 18: 411-420, 1998.
35. Miyakawa H, Kira S, Okuda K, Takeshima N, Mori M, Noguchi T. Olprinone decreases elevated concentrations of cytokine-induced neutrophil chemoattractant-1 in septic rats. J Anesth 22: 27-31, 2008.
36. Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone, a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev 20: 163-174, 2002.
37. Monick MM, Carter AB, Robeff PK, Flaherty DM, Peterson MW, Hunninghake GW. Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of β-catenin. J Immunol 166: 4713-4720, 2001.
38. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PGM, Schmidt M, Eisel ULM. Neuronal AKAP150 coordinates PKA and Epac-mediated PKB/ Akt phosphorylation. Cell Signal 20: 1715-1724, 2008.
39. Nijjar MS. Role of cyclic AMP and related enzymes in rat lung growth and development. Biochim Biophys Acta 586: 464-472, 1979.
40. Pyne NJ, Burns F. Lung phosphodiesterase isoenzymes. Agents Actions Suppl 43: 35-49, 1993.
41. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 112: 460-467, 2003.
42. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35: 1599-1608, 2007.
43. Romashkova JA, Makarov SS. NF-κB is a target of AKT in antiapoptotic PDGF signaling. Nature 401: 86-90, 1999.
44. Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 20: 460-466, 2008.
45. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47: 127-162, 2000.
46. Souza DG, Cassali GD, Pooles S, Teixeira MM. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries flowing ischaemia and reperfusion injury. Br J Pharmacol 134: 985-994, 2001.
47. Takano K, Yamamoto S, Tomita K, Takashina M, Yokoo H, Matsuda N, Takano Y, Hattori Y. Successful treatment of acute lung injury with pitavastatin in septic mice: potential role of glucocorticoid receptor expression in alveolar macrophages. J Pharmacol Exp Ther 336: 381-390, 2011.
48. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18: 164-171, 1997.
49. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254, 1999.
50. Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G, Szabo C, Sumegi B. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 65: 1373-1382, 2003.
51. Weshe-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 106: 2295-2301, 2005.
52. Ye X, Liu SF. Lipopolysaccharide regulates constitutive and inducible transcription factor activities differentially in vivo in the rat. Biochem Biophys Res Commun 288: 927-932, 2001.